162 related articles for article (PubMed ID: 30954944)
1. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA; Liu S; Bugge TH; Torres JB; Mosley M; Hopkins SL; Allen PD; Berridge G; Vendrell I; Fischer R; Kersemans V; Smart S; Leppla SH; Cornelissen B
J Nucl Med; 2019 Oct; 60(10):1474-1482. PubMed ID: 30954944
[TBL] [Abstract][Full Text] [Related]
2. Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA.
Xavier ME; Liu S; Leppla SH; Cornelissen B
Nucl Med Biol; 2019; 72-73():49-54. PubMed ID: 31330412
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Liu S; Netzel-Arnett S; Birkedal-Hansen H; Leppla SH
Cancer Res; 2000 Nov; 60(21):6061-7. PubMed ID: 11085528
[TBL] [Abstract][Full Text] [Related]
4. Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
Rozanov DV; Golubkov VS; Strongin AY
Int J Biochem Cell Biol; 2005 Jan; 37(1):142-54. PubMed ID: 15381157
[TBL] [Abstract][Full Text] [Related]
5. Role of toxin functional domains in anthrax pathogenesis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564
[TBL] [Abstract][Full Text] [Related]
6. An anthrax toxin variant with an improved activity in tumor targeting.
Wein AN; Peters DE; Valivullah Z; Hoover BJ; Tatineni A; Ma Q; Fattah R; Bugge TH; Leppla SH; Liu S
Sci Rep; 2015 Nov; 5():16267. PubMed ID: 26584669
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulations of complexes between wild-type and mutant anthrax protective antigen variants and a model anthrax toxin receptor.
Stiles L; Nelson DJ
J Biomol Struct Dyn; 2005 Apr; 22(5):503-19. PubMed ID: 15702923
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
10. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
Liu S; Ma Q; Fattah R; Bugge TH; Leppla SH
Oncotarget; 2017 Sep; 8(39):65123-65131. PubMed ID: 29029417
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
13. Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Panchal RG; Halverson KM; Ribot W; Lane D; Kenny T; Abshire TG; Ezzell JW; Hoover TA; Powell B; Little S; Kasianowicz JJ; Bavari S
J Biol Chem; 2005 Mar; 280(11):10834-9. PubMed ID: 15644338
[TBL] [Abstract][Full Text] [Related]
14. Lethal factor of anthrax toxin binds monomeric form of protective antigen.
Chvyrkova I; Zhang XC; Terzyan S
Biochem Biophys Res Commun; 2007 Aug; 360(3):690-5. PubMed ID: 17617379
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity of anthrax and C2 toxin: protective antigen promotes the uptake of botulinum C2I toxin into human endothelial cells.
Kronhardt A; Rolando M; Beitzinger C; Stefani C; Leuber M; Flatau G; Popoff MR; Benz R; Lemichez E
PLoS One; 2011; 6(8):e23133. PubMed ID: 21850257
[TBL] [Abstract][Full Text] [Related]
16. Anthrax toxin.
Bhatnagar R; Batra S
Crit Rev Microbiol; 2001; 27(3):167-200. PubMed ID: 11596878
[TBL] [Abstract][Full Text] [Related]
17. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
18. Anthrax protective antigen cleavage and clearance from the blood of mice and rats.
Moayeri M; Wiggins JF; Leppla SH
Infect Immun; 2007 Nov; 75(11):5175-84. PubMed ID: 17724066
[TBL] [Abstract][Full Text] [Related]
19. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.
Nguyen ML; Terzyan S; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Nov; 77(11):4714-23. PubMed ID: 19720758
[TBL] [Abstract][Full Text] [Related]
20. Changing the receptor specificity of anthrax toxin.
Mechaly A; McCluskey AJ; Collier RJ
mBio; 2012; 3(3):. PubMed ID: 22550037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
